Business Description
Rigel Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US7665597024
Share Class Description:
RIGL: Ordinary SharesTotal Employee Number:
174Description
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.21 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | 0.35 | |||||
Interest Coverage | 18.05 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 3.07 | |||||
Beneish M-Score | 1.6 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 30.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -15.76 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.69 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 74.62 | |||||
9-Day RSI | 76.87 | |||||
14-Day RSI | 74.41 | |||||
3-1 Month Momentum % | 9.04 | |||||
6-1 Month Momentum % | -28.23 | |||||
12-1 Month Momentum % | 60.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.62 | |||||
Quick Ratio | 2.48 | |||||
Cash Ratio | 1.64 | |||||
Days Inventory | 189.86 | |||||
Days Sales Outstanding | 55.79 | |||||
Days Payable | 98.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.8 | |||||
Shareholder Yield % | 1.24 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 93.39 | |||||
Operating Margin % | 41.56 | |||||
Net Margin % | 121.51 | |||||
EBITDA Margin % | 43.79 | |||||
FCF Margin % | 26.44 | |||||
OCF Margin % | 26.44 | |||||
ROE % | 180.4 | |||||
ROA % | 110.81 | |||||
ROIC % | 63.87 | |||||
3-Year ROIIC % | 59.31 | |||||
ROC (Joel Greenblatt) % | 755.61 | |||||
ROCE % | 53.38 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 2.07 | |||||
Forward PE Ratio | 10.86 | |||||
PE Ratio without NRI | 2.07 | |||||
Price-to-Owner-Earnings | 2.19 | |||||
PS Ratio | 2.47 | |||||
PB Ratio | 1.79 | |||||
Price-to-Tangible-Book | 1.9 | |||||
Price-to-Free-Cash-Flow | 9.31 | |||||
Price-to-Operating-Cash-Flow | 9.31 | |||||
EV-to-EBIT | 4.78 | |||||
EV-to-Forward-EBIT | 7.15 | |||||
EV-to-EBITDA | 4.69 | |||||
EV-to-Forward-EBITDA | 7.15 | |||||
EV-to-Revenue | 2.05 | |||||
EV-to-Forward-Revenue | 2.21 | |||||
EV-to-FCF | 7.76 | |||||
Price-to-GF-Value | 1.38 | |||||
Price-to-Projected-FCF | 3.16 | |||||
Price-to-Median-PS-Value | 0.61 | |||||
Price-to-Graham-Number | 0.42 | |||||
| Price-to-Net-Current-Asset-Value | 5.53 | |||||
| Price-to-Net-Cash | 17.06 | |||||
Earnings Yield (Greenblatt) % | 20.92 | |||||
FCF Yield % | 11.07 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RIGL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rigel Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 299.767 | ||
| EPS (TTM) ($) | 18.72 | ||
| Beta | 3.3027 | ||
| 3-Year Sharpe Ratio | 0.63 | ||
| 3-Year Sortino Ratio | 1.41 | ||
| Volatility % | 116.18 | ||
| 14-Day RSI | 74.41 | ||
| 14-Day ATR ($) | 1.604207 | ||
| 20-Day SMA ($) | 34.386 | ||
| 12-1 Month Momentum % | 60.97 | ||
| 52-Week Range ($) | 18.24 - 52.24 | ||
| Shares Outstanding (Mil) | 18.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rigel Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rigel Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 16:30 | In 123 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 122 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | In 32 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 31 days | ||
| Jefferies Global Healthcare Conference | 2026-06-03 08:45 | 30.02 (+2.14%) | ||
| Guidance call for 2026 | 2026-05-19 09:30 | 28.61 (-1.34%) | ||
| General meeting for 2026 | 2026-05-14 07:30 | 32.13 (+6.32%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 16:30 | 29.54 (+0.48%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 29.54 (+0.48%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-03 16:30 | 34.62 (+1.85%) |
Show
Entries
Rigel Pharmaceuticals Inc Frequently Asked Questions
What is Rigel Pharmaceuticals Inc(RIGL)'s stock price today?
The current price of RIGL is $38.72. The 52 week high of RIGL is $52.24 and 52 week low is $18.24.
When is next earnings date of Rigel Pharmaceuticals Inc(RIGL)?
The next earnings date of Rigel Pharmaceuticals Inc(RIGL) is 2026-08-05 Est..
Does Rigel Pharmaceuticals Inc(RIGL) pay dividends? If so, how much?
Rigel Pharmaceuticals Inc(RIGL) does not pay dividend.
Guru Commentaries on NAS:RIGL
No articles.
Press Release
Articles on Rigel Pharmaceuticals Inc
No articles.
Headlines
See More- 1
Jun 17, 2026
Rigel to roll out Veppanu in August; Arvinas, Pfizer snag $70M upfront on cleared deal
Seeking Alpha • 2:17am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers